About us Contacts Drug interactions: 390 212
Drug search by name

Digox and Prilosec (Omeprazole Powder for Oral Suspension)

Determining the interaction of Digox and Prilosec (Omeprazole Powder for Oral Suspension) and the possibility of their joint administration.

Check result:
Digox <> Prilosec (Omeprazole Powder for Oral Suspension)
Relevance: 26.06.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Talk to your doctor before using digoxin together with omeprazole. Drugs known as proton pump inhibitors including omeprazole may increase the effects of digoxin. In the short-term, omeprazole can occasionally cause an increase in the blood levels of digoxin. You should seek immediate medical attention if you experience signs and symptoms that may indicate excessive effects of digoxin, such as nausea, vomiting, diarrhea, loss of appetite, visual disturbances (blurred vision; light halos around objects; green or yellow vision), or an abnormally fast or slow or uneven heartbeat. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. If you continue to take omeprazole for a prolonged period (for example, several months to a year or more), you may develop a condition called hypomagnesemia, or low blood magnesium. Hypomagnesemia can increase the sensitivity of your heart to the effects of digoxin and cause toxicity even if your digoxin levels are within range. Let your doctor know if you develop symptoms of hypomagnesemia such as irregular heart rhythm, palpitations, muscle spasm, tremor, or seizures. In children, abnormal heart rhythm may cause fatigue, upset stomach, dizziness, and lightheadedness. If you are using an over-the-counter proton pump inhibitor medication such as Prilosec OTC, Zegerid OTC or Prevacid 24 HR, you should follow the directions on the package carefully. Do not use the medication more frequently or for a longer period than recommended on the label unless otherwise prescribed by your doctor. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Proton pump inhibitors may increase the bioavailability of digoxin. The mechanism may involve a pH-dependent increase in gastrointestinal absorption of digoxin and/or inhibition by PPIs of the P-glycoprotein-mediated intestinal transport of digoxin. In pharmacokinetic studies, digoxin systemic exposure (AUC) increased by an average of 10% to 20% when administered with omeprazole, pantoprazole, or rabeprazole. These changes are generally not considered clinically significant. However, a case report describes a 65-year-old patient who exhibited signs of digoxin toxicity and ECG changes three months after starting treatment with omeprazole 20 mg/day. Her digoxin level was 3.9 ng/mL, and she was treated with digoxin immune Fab.

MONITOR: Coadministration with proton pump inhibitors (PPIs) for prolonged periods may increase the risk of digoxin toxicity. Chronic use of PPIs can induce hypomagnesemia. In patients with hypomagnesemia, toxicity may occur despite serum digoxin concentrations below 2.0 ng/mL because magnesium depletion sensitizes the myocardium to digoxin. The mechanism via which hypomagnesemia may occur during long-term PPI use is unknown, although changes in intestinal absorption of magnesium may be involved. Hypomagnesemia has been reported rarely in patients treated with PPIs for at least three months, but in most cases, after a year or more. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the U.S. Food and Drug Administration, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI. Both positive dechallenge as well as positive rechallenge (i.e., resolution of hypomagnesemia with PPI cessation and recurrence with PPI resumption) were reported in some cases. After discontinuing the PPI, the median time required for magnesium levels to normalize was one week. After restarting the PPI, the median time for hypomagnesemia to recur was two weeks.

MANAGEMENT: Caution is advised if digoxin is prescribed in combination with PPIs. Pharmacologic response and serum digoxin levels should be monitored more closely following the addition or discontinuation of PPI therapy, and the digoxin dosage adjusted as necessary. Patients should be advised to notify their physician if they experience potential signs and symptoms of digoxin toxicity such as nausea, anorexia, visual disturbances, slow pulse, or irregular heartbeats. Monitoring of serum magnesium levels is recommended prior to initiation of PPI therapy and periodically thereafter if prolonged treatment is anticipated or when combined with other agents that can cause hypomagnesemia (e.g., diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, tacrolimus). Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.

References
  • "Product Information. Aciphex (rabeprazole)" Janssen Pharmaceuticals, Titusville, NJ.
  • "Product Information. Nexium (esomeprazole)" Astra-Zeneca Pharmaceuticals, Wilmington, DE.
  • Le GH, Schaefer MG, Plowman BK, et al. "Assessment of potential digoxin-rabeprazole interaction after formulary conversion of proton-pump inhibitors." Am J Health Syst Pharm 60 (2003): 1343-5
  • "Product Information. Prilosec (omeprazole)." Merck & Co, Inc, West Point, PA.
  • Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN "Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose." Br J Clin Pharmacol 32 (1991): 569-72
  • "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America, Lincolnshire, IL.
  • Kiley CA, Cragin DJ, Roth BJ "Omeprazole-associated digoxin toxicity." South Med J 100 (2007): 400-2
  • "Product Information. Protonix (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  • FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm." ([2011 Mar 2]):
  • Andersson T "Omeprazole drug interaction studies." Clin Pharmacokinet 21 (1991): 195-212
  • "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc, Deerfield, IL.
Digox

Generic Name: digoxin

Brand name: Digitek, Digox, Lanoxin, Lanoxicaps, Cardoxin

Synonyms: Digox (Oral), Digox Tablets

Prilosec (Omeprazole Powder for Oral Suspension)

Generic Name: omeprazole

Brand name: FIRST Omeprazole, Omeprazole + SyrSpend SF Alka, Prilosec, Prilosec OTC, Prilosec, Prilosec OTC, Zegerid>

Synonyms: Prilosec

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.